We are live on ! Find out more
AC

Aaron Cowen Suvretta Capital Management

AUM $5.47B
1-Year Est. Return 131.34%
 

Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.

This Fund
S&P 500
This Quarter Est. Return
+39.89%
1 Year Est. Return
+131.34%
3 Year Est. Return
+363.85%
5 Year Est. Return
+515.73%
10 Year Est. Return
+2,786.05%
AUM
$5.47B
AUM Growth
+$1.55B
Cap. Flow
+$555M
Cap. Flow %
10.15%
Top 10 Hldgs %
49.14%
Holding
110
New
21
Increased
26
Reduced
17
Closed
14

Top Buys

Rank Stock Value
1
AVLN
Avalyn Pharma
AVLN
+$72.2M
2
HUT
Hut 8
HUT
+$65M
3
SPOT icon
Spotify
SPOT
+$48M
4
FTH
Faeth Therapeutics
FTH
+$45.9M
5
CBRS
Cerebras Systems
CBRS
+$40.5M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$142M
2
KALV
KalVista Pharmaceuticals
KALV
+$96M
3
ERAS icon
Erasca
ERAS
+$55.6M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$37.4M
5
PFGC icon
Performance Food Group
PFGC
+$35.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.49%
2 Technology 10.26%
3 Consumer Discretionary 5.22%
4 Financials 4.29%
5 Industrials 3.72%

No holdings matched the selected filter criteria.

1 2 3 4 5

Similar funds

NC
Nicholas Company Milwaukee, Wisconsin $5.47B AUM 16.96% 1-Year Est. Return
EI
EFG International Zurich $5.46B AUM
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
ENV
Exor N.V. Amsterdam, Netherlands $5.46B AUM 6.21% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
VCM
Voleon Capital Management Berkeley, California $5.49B AUM 56.94% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
TPCW
TD Private Client Wealth New York $5.44B AUM 18.56% 1-Year Est. Return

Aaron Cowen's Q2 2026 Portfolio in Review

As of Q2 2026, Aaron Cowen held 110 positions worth $5.47B, up 40% from $3.92B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Aaron Cowen deployed $555M of net new capital in Q2 2026, opening 21 new positions and adding to 26 existing holdings. Its largest new stake was Avalyn Pharma: 2,503,109 shares worth $82.4M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 65% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Mineralys Therapeutics, an estimated $37.4M trimmed.

  • Aaron Cowen's largest Q2 2026 buy was Avalyn Pharma: 2,503,109 shares worth $82.4M.
  • Aaron Cowen added most to Spotify in Q2 2026, an estimated $48M increase.
  • Aaron Cowen's biggest Q2 2026 reduction was Mineralys Therapeutics, cutting an estimated $37.4M.
  • Aaron Cowen fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $142M.
  • Aaron Cowen's ten largest holdings make up 49% of its $5.47B portfolio in Q2 2026.
  • Aaron Cowen opened 21 new positions and closed 14 in Q2 2026.
  • Aaron Cowen's portfolio value rose 40% quarter-over-quarter to $5.47B.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.